Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients

Haematologica

Volumn 100, Issue 1, 2015, Pages 107-113

  Blimark, Cecilie ^a   Holmberg, Erik ^b   Mellqvist, Ulf Henrik ^a   Landgren, Ola ^c   Bjorkholm, Magnus ^d   Hultcrantz, Malin ^d   Kjellander, Christian ^d   Turesson, Ingemar ^e   Kristinsson, Sigurdur Y ^d,f  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; MELPHALAN; STEROID; THALIDOMIDE;

ADULT; AGE; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELLULITIS; CONTROLLED STUDY; DEATH; ENDOCARDITIS; FEMALE; GENDER; HERPES ZOSTER; HUMAN; INFECTION; INFECTION RISK; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOMYELITIS; PNEUMONIA; PYELONEPHRITIS; SEPTICEMIA; VERY ELDERLY; ADVERSE EFFECTS; BACTERIAL INFECTIONS; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; REGISTER; SURVIVAL RATE; SWEDEN; VIRUS DISEASES;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; REGISTRIES; SURVIVAL RATE; SWEDEN; VIRUS DISEASES;

EID: 84920175072     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.107714     Document Type: Article

References (32)

1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-8.
2. Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28(6):1346-8.
3. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a populationbased study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25(15):1993-9.
4. Palumbo A, Mina R. Management of older adults with multiple myeloma. Blood Rev. 2013;27(3):133-42.
5. Kyle RA, Rajkumar S. Multiple myeloma. N Engl J Med. 2004;351:1860-73.
6. Nucci M. AE. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009.(49):1211–25.
7. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005; 23(36):9219-26.
8. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007; 138(5):563-79.
9. Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, Blimark C, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012; 97(6):854-8.
10. Gregersen H, Madsen KM, Sorensen HT, Schonheyder HC, Ibsen JS, Dahlerup JF. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. Eur J Haematol. 1998;61(2): 140-4.
11. Karlsson J, Andreasson B, Kondori N, Eman E, Rieabeck K, Hogevik K, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol. 2011;18(6):969-77.
12. Hargreaves RM, Lea JR, Griffiths H, Faux JA, Holt JM, Reid C, et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol. 1995;48(3): 260-6.
13. Offidani M, Corvatta L, Polloni C, Gentili S, Brioni A, Visani G, et al. Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. Leuk Lymphoma. 2011;52(5):776-85.
14. Afessa B, Peters SG. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med. 2006;27(3):297-309.
15. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008; 26(29):4784-90.
16. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of highdose therapy and novel agents. Clin Infect Dis. 2009;49(8):1211-25.
17. Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor sur vival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013; 98(6):980-7.
18. Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR, Caporaso NE, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121(10):2260-6.
19. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
20. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol. 2010;28(5):830-4.
21. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000;95(1):7-11.
22. Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wislöff F, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol. 2006;133(4):389-96.
23. Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Joliusson G, et al. Cyclophosphamide plus dexamethasone is an efficient initial treatment before highdose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Cancer. 2008;112(1):129-35.
24. Blimark C, Holmberg E, Juliusson G, Nahi H, Forsberg K, Turesson I, et al. Real World data in Myeloma: Experiences from the Swedish Population-based Registry on 2494 Myeloma Patients Diagnosed 2008-2011. Blood 2013;122:1972[Abstract].
25. Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Bjorkstrand B, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116(9): 1405-12.
26. Twomey JJ. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med. 1973; 132(4):562-5.
27. Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med. 1982; 96(1):47-50.
28. Caravita T, Offidani M, Siniscalchi A, Gentili S, Caraffa P, Perrotti A, et al. Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations. Eur J Haematol. 2012;89(3):276-7.
29. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet. 1994;343 (8905):1059-63.
30. Cesana C, Nosari AM, Klersy C, Miqueleiz S, Rossi V, Ferrando P, et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. Haematologica. 2003;88(9): 1022-8.
31. Millett ER, Quint JK, Smeeth L, Daniel RM, Thomas SL. Incidence of communityacquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. PLoS One. 2013;8(9):e75131.
32. Vesole DH, Oken MM, Heckler C, Greipp PR, Katz MS, Jacobus S, et al. Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study. Leukemia. 2012; 26(12): 2517-20.